OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

The U.S. is the first region in which the trial will resume patient accrual under the revised protocol. By focusing exclusively on NSCLC patients who have failed a previous treatment with PD-1/PD-L1 immune checkpoint inhibitors…